Investigating a marker for severe asthma in children
Cross-sectional Pilot Study of the Alveolar and Serum sRAGE Biomarker in Severe Asthma in Children.
This study is testing if a blood marker called sRAGE can help doctors understand and manage severe asthma in children better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 85 (estimated) |
| Ages | 1 Day to 16 Years |
| Sex | All |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Locations | 1 site (Clermont-Ferrand) |
| Trial ID | NCT05364996 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the role of soluble receptor for advanced glycation end products (sRAGE) as a potential biomarker for severe asthma in children. It involves collecting blood samples and performing bronchial endoscopy with bronchoalveolar lavage to assess levels of sRAGE and its correlation with asthma severity. The study aims to better understand the inflammatory processes in pediatric asthma and how sRAGE levels may reflect disease control. By examining these relationships, the research seeks to contribute to the understanding of asthma management in children.
Who should consider this trial
Good fit: Ideal candidates for this study are children diagnosed with severe asthma who weigh at least 5 kg.
Not a fit: Patients with current respiratory infections or other specified comorbidities such as cystic fibrosis or autoimmune diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for managing severe asthma in children.
How similar studies have performed: While few studies have explored sRAGE in asthma, preliminary findings suggest a potential link, indicating that this approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * severe asthma * Weight greater than or equal to 5 kg Exclusion Criteria: * Current respiratory infection * Bronchopulmonary dysplasia or prematurity \< 34 weeks * Diffuse infiltrative pneumonia * Cystic fibrosis, primary ciliary dyskinesia * Known immune deficiencies; * Congenital heart disease; * Cardiomyopathy; * Ongoing pericarditis, myopericarditis, endocarditis; * Chronic valvular pathology; * Known autoimmune disease; * Neuromuscular pathology;
Where this trial is running
Clermont-Ferrand
- CHU de Clermont-Ferrand — Clermont-Ferrand, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.